Metabiomics will describe its approach for developing a sequencing-based, non-invasive screening test for colorectal cancer at the Colorado Capital Conference and OCTANe Medical Device & Investor Forum
Potomac Falls, Virginia (October 5, 2012)
Metabiomics, an early stage molecular diagnostics firm, will visit Denver, Colorado and Orange County, California next week to present a business plan and growth strategy for commercializing a non-invasive screening test for colorectal cancer. Metabiomics was selected as 1 of 14 presenting companies at the Colorado Capital Conference on October 9 in Denver, and of 1 of 9 companies presenting at the OCTANe Medical Device & Investor Forum on October 10 in Orange County.
Both the Rockies Venture Club and OCTANe events are geared towards connecting investors and entrepreneurs in an effort to catalyze growth of promising high-tech start-ups. “We are happy to be telling our story in Colorado and California,” said Greg Kuehn, Metabiomics’ Vice President of Business Development. “Colorectal cancer is a global problem, and next-generation DNA sequencing is a powerful new tool with the potential to stop it in its tracks.” Colorectal cancer causes more than 52,000 deaths a year and costs about $14 billion annually to treat in the US. If colon polyps are detected early, they can be removed, which stops the cancer before it even gets started. Unfortunately, almost 47% of Americans skip invasive colonoscopy screening tests, resulting in a dismal 60% of new cancer cases not being detected until stage 3 and later.
“There is such great value in a non-invasive approach to colorectal cancer detection because of its potential for dislodging colonoscopy as a first-line screening test,” said Dr. Thomas Kuehn, President and CEO of Metabiomics. “It is less costly at every step in the value chain, from development, through commercialization and delivery. But the greatest benefit of course comes from stopping the progression of colon cancer.”
About the Colorado Capital Conference: The 24th Colorado Capital Conference will be held at the EXDO Hall in North Denver on October 8-9 and features two seminar tracks for investors and entrepreneurs as well as 14 company pitches. Colorado Governor John Hickenlooper will deliver the Keynote address on Tuesday October 9 at 11:30. Event Website: http://www.coloradocapitalconference.org
About the OCTANe Medical Device and Investor Forum: The 7th Annual Medical Device and Investor Forum is a signature event of OCTANe, an Orange County startup accelerator dedicated to connecting people and ideas with capital and resources to fuel technology growth. The event attracts more than 7,000 attendees each year and will take place at the Hyatt Regency in Irvine, CA on Oct. 10-11. Event Website: http://www.mdif2012.com/main.htmlMetabiomics Safe Harbor Statement: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the potential results and future outcomes our clinical research and business plan; ability to discover biomarkers and diagnostic tests; our beliefs regarding the need for and value of molecular diagnostics; and the focus and attributes of the company’s product pipeline, including the ability of the company’s tests to impact clinical practice. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the results of clinical and developmental studies; the applicability of clinical study results to actual outcomes; our ability to develop and commercialize new tests and the timing thereof; unanticipated costs or delays in research and development efforts; the applicability of initial next generation sequencing studies to future results; the risk that we may not obtain or maintain reimbursement for diagnostic tests we may develop, both domestically and abroad; our ability to compete against third parties; the risks and uncertainties associated with the regulation of our tests by the FDA and other agencies abroad; and the other risks set forth in the company’s business plans and presentations. These forward- looking statements speak only as of the date hereof. Metabiomics disclaims any obligation to update these forward-looking statements.